A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Owen A O'CONNOR; Carol PORTLOCK; Craig MOSKOWITZ; David STRAUS; Paul HAMLN; Michael STUBBLEFIELD; Otila DUMETRESCU; A DIMITRIOS COLEVAS; Barbara GRANT; Andrew ZELENETZ

doi:10.1111/j.1365-2141.2008.07271.x

$A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma$

Journal article

Peer reviewed

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Owen A O'CONNOR, Carol PORTLOCK, Craig MOSKOWITZ, David STRAUS, Paul HAMLN, Michael STUBBLEFIELD, Otila DUMETRESCU, A DIMITRIOS COLEVAS, Barbara GRANT and Andrew ZELENETZ

British journal of haematology, Vol.143(2), pp.201-209

2008

DOI: https://doi.org/10.1111/j.1365-2141.2008.07271.x

PMID: 18691173

Abstract

Hematologic and hematopoietic diseases

Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis

Biological and medical sciences

Medical sciences

Metrics

8 Record Views

13 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.219 Cancer Drugs; 1.219.1208 Paclitaxel
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
Creators: Owen A O'CONNOR - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
Carol PORTLOCK - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
Craig MOSKOWITZ - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
David STRAUS - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
Paul HAMLN - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
Michael STUBBLEFIELD - Department of Rehabilitation Medicine, Memorial Sloan Kettering Cancer Center, United States
Otila DUMETRESCU - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
A DIMITRIOS COLEVAS - Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD, United States
Barbara GRANT - Vermont Cancer Center, University of Vermont, Burlington, VT, United States
Andrew ZELENETZ - Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, United States
Publication Details: British journal of haematology, Vol.143(2), pp.201-209
Publisher: Blackwell; Oxford
Academic Unit: Miller School of Medicine; UMMG Department of Medicine
Language: English
Resource Type: Journal article
PMID: 18691173
Record Identifier: 991031562219402976